Lenalidomide after Stem-Cell Transplantation for Multiple MyelomaPhilip L. McCarthy, Charles Linker, Kouros Owzar et al.|New England Journal of Medicine|2012Cited by 1.1k
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic SyndromesBart L. Scott, Mitchell E. Horwitz, Marcelo C. Pasquini et al.|Journal of Clinical Oncology|2017Cited by 664
Triplet Therapy, Transplantation, and Maintenance until Progression in MyelomaPaul G. Richardson, Irene M. Ghobrial, Susanna Jacobus et al.|New England Journal of Medicine|2022Cited by 457
Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual DiseaseChristopher S. Hourigan, Mitchell E. Horwitz, Laura W. Dillon et al.|Journal of Clinical Oncology|2019Cited by 441
One million haemopoietic stem-cell transplants: a retrospective observational studyAloïs Gratwohl, Dietger Niederwieser, Marcelo C. Pasquini et al.|The Lancet Haematology|2015Cited by 434